Novartis to buy Chinook for up to US$3.5 billion
Novartis said on Monday (Jun 12) it agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to US$3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.
The transaction, in the form of a merger of a newly formed Novartis subsidiary and Chinook, is expected to close in the second half of 2023, the Swiss drugmaker said in a statement.
Under the agreed deal, Chinook shareholders would receive US$3.2 billion, or US$40 per share, in cash plus a contingent value right worth up to US$300 million, depending on certain regulatory achievements, it said.
Chinook shares closed at US$23.99 on Friday.
The US biotech firm expects to see the pivotal readout in the fourth quarter of this year of a clinical trial in the third and last stage of development of oral drug candidate atrasentan to treat a kidney disease known as IgAN.
Chinook also has zigakibart, another experimental IgAN treatment, under development and plans to start a Phase 3 in the third quarter of 2023. REUTERS
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Olam tops Louis Dreyfus’ offer for Australia’s Namoi Cotton as takeover battle heats up
UG Healthcare fully acquires German subsidiary for 16.9 million euros
Daiwa House Logistics Trust posts 0.6% higher Q1 distributable income
Stocks to watch: UOB, DBS, Olam, Far East Orchard, Daiwa House Logistics Trust, Manulife US Reit
Twilio forecasts quarterly revenue below estimates on weak enterprise spending
Fed’s Kashkari says rates likely on hold for ‘extended period’